This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
D. Aarsland , U. P. Mosimann and I. G. McKeith (2004). Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology, 17, 164–171.
D. Aarsland (2005). Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Journal of Clinical Psychiatry, 66, 633–637.
T. S. Benamer (2000). Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Movement Disorders, 15, 503–510.
R. Ceravolo (2003). Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurological Sciences, 24, 162–163.
M. Firbank , S. J. Colloby , D. Burn , I. G. McKeith and J. T. O'Brien (2003). Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage, 20, 1309–1319.
M. F. Folstein , S. E. Folstein and P. R. McHugh (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
S. Gilman (2005). Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18 F]fluorodeoxyglucose and neuropsychological testing. Experimental Neurology, 191 (Suppl. 1), S95–S103.
H. Hanyu (2006a). Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 33, 248–253.
H. Hanyu (2006b). Differentiation of dementia with lewy bodies from Alzheimer's disease using Mini-Mental State Examination and brain perfusion SPECT. Journal of the Neurological Sciences, 250, 97–102.
M. B. Imran (1999). Tc-99 m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. Journal of Neurology, Neurosurgery and Psychiatry, 66, 228–232.
K. Ishii (1998). Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology, 51, 125–130.
K. Ishii , M. Sasaki , S. Sakamoto , S. Yamaji , H. Kitagaki and E. Mori (1999a). Tc-99 m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-D-glucose PET in Alzheimer's disease: comparison of perfusion and metabolic patterns. Clinical Nuclear Medicine, 24, 572–575.
K. Ishii , S. Yamaji , H. Kitagaki , T. Imamura , N. Hirono and E. Mori (1999b). Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology, 53, 413–416.
P. M. Kemp , S. A. Hoffmann , L. Tossici-Bolt , J. S. Fleming and C. Holmes (2007). Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nuclear Medicine Communications, 28, 451–456.
Y. C. Lee (2003). Statistical parametric mapping of brain SPECT perfusion abnormalities in patients with Alzheimer's disease. European Neurology, 49, 142–145.
K. Lobotesis (2001). Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology, 56, 643–649.
I. G. McKeith , A. F. Fairbairn , R. H. Perry and P. Thompson (1994). The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). British Journal of Psychiatry, 165, 324–332.
I. G. McKeith (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 47, 1113–1124.
I. G. McKeith (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 65, 1863–1872.
I. McKeith (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, 6, 305–313.
G. McKhann , D. Drachman , M. Folstein , R. Katzman , D. Price and E. M. Stadlan (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.
S. Minoshima , N. L. Foster , A. A. F. Sima , K. A. Frey , R. L. Albin and D. E. Kuhl (2001). Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Annals of Neurology, 50, 358–365.
J. T. O'Brien (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology, 61, 919–925.
T. Oide (2003). Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Internal Medicine, 42, 686–690.
J. Pasquier , B. F. Michel , I. Brenot-Rossi , N. Hassan-Sebbag , R. Sauvan and J. L. Gastaut (2002). Value of (99 m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging, 29, 1342–1348.
M. Roth (1986). CAMDEX: a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. British Journal of Psychiatry, 149, 698–709.
S. Shimizu , H. Hanyu , H. Kanetaka , T. Iwamoto , K. Koizumi and K. Abe (2005). Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. Dementia and Geriatric Cognitive Disorders, 20, 25–30.
Z. Walker (2002). Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. Journal of Neurology, Neurosurgery and Psychiatry, 73, 134–140.
Z. Walker (2007). Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. Journal of Neurology, Neurosurgery and Psychiatry, 78, 1176–1181.